International Myeloma Society Annual Meeting | Conference

Myeloma Experts Summarize Key Themes From the 22nd Annual IMS Meeting and Exposition

September 23rd 2025

OncLive heard from myeloma experts about the biggest developments in the field at the 22nd Annual International Myeloma Society Meeting and Exposition.

Isa-VRd Displays High VGPR or Better Rate in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

September 22nd 2025

Isa-VRd produced a VGPR or better rate of 87.8% in transplant-ineligible newly diagnosed multiple myeloma.

Sonrotoclax Plus Dexamethasone Generates Early Efficacy in R/R Myeloma

September 21st 2025

Sonrotoclax plus dexamethasone was well tolerated and produced early efficacy signals in relapsed/refractory multiple myeloma with t(11;14).

BKd Produces Robust Responses in Relapsed/Refractory Multiple Myeloma

September 20th 2025

Belantamab mafodotin plus carfilzomib and dexamethasone was active in patients with relapsed/refractory multiple myeloma.

Belantamab Mafodotin/Lenalidomide Maintenance Displays Manageable Eye Toxicity Profile in Newly Diagnosed Myeloma

September 20th 2025

Belantamab mafodotin plus lenalidomide maintenance was active and had an expected safety profile in transplant-eligible, newly diagnosed myeloma.

Belantamab Mafodotin Shows Single-Agent Activity in Relapsed/Refractory Multiple Myeloma

September 20th 2025

Belantamab mafodotin monotherapy was active and safe in patients with relapsed/refractory multiple myeloma.

Dr Leleu on QOL Outcomes With SC Isatuximab Via On-Body Delivery in R/R Myeloma

September 20th 2025

Xavier Leleu, MD, PhD, discusses the role of subcutaneous isatuximab delivered via an on-body delivery system in patients with relapsed/refractory multiple myeloma.

ATLAS Analysis Supports KRd After ASCT in High-Risk, Newly Diagnosed Myeloma

September 20th 2025

Carfilzomib, lenalidomide, and dexamethasone after transplant improved PFS and OS in high-risk, newly diagnosed multiple myeloma.

Subcutaneous Isatuximab Delivery Is Noninferior to IV Administration in Multiple Myeloma

September 20th 2025

Efficacy and pharmacokinetic measures with IV vs SC isatuximab delivered via an on-body injector were comparable in patients with multiple myeloma.

Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Newly Diagnosed Myeloma

September 20th 2025

Maintenance therapy with daratumumab plus lenalidomide led to higher MRD-negativity conversion rates vs lenalidomide alone in newly diagnosed myeloma.

Dr Anderson on Daratumumab/Lenalidomide Maintenance After ASCT in Newly Diagnosed Myeloma

September 20th 2025

Larry Anderson, MD, PhD, discusses updated efficacy and safety findings of subcutaneous daratumumab plus lenalidomide in newly diagnosed multiple myeloma following autologous stem cell transplant.

Linvoseltamab Yields Favorable Safety Profile and Antimyeloma Activity in High-Risk Smoldering Myeloma

September 19th 2025

Linvoseltamab monotherapy generated responses and had a favorable safety profile with low rates of high-grade TEAEs in high-risk smoldering myeloma.

Belantamab Mafodotin/Bortezomib/Dexamethasone Yields PFS, OS Benefits in Lenalidomide-Refractory Myeloma

September 19th 2025

Treatment with BVd led to favorable survival outcomes and prolonged responses vs DVd in lenalidomide-refractory patients with multiple myeloma.

Daratumumab/Ixazomib Quadruplet Yields Durable Efficacy in Transplant-Ineligible or -Deferred, Newly Diagnosed Myeloma

September 19th 2025

The combination of daratumumab, lenalidomide, ixazomib, and dexamethasone was efficacious in transplant-ineligible, newly diagnosed myeloma.

Stretched Dosing Schedule of Belantamab Mafodotin Plus VRd Is Active, Safe in Transplant-Ineligible Myeloma

September 19th 2025

The addition of belantamab mafodotin to standard-of-care VRd proved feasible as frontline therapy in newly diagnosed multiple myeloma.

Dr Nadeem on Efficacy and Safety of Arlo-Cel for R/R Myeloma

September 19th 2025

Omar Nadeem, MD, discusses updated data with the GPRC5D-targeted CAR T-cell therapy arlocabtagene autoleucel in relapsed/refractory multiple myeloma.

Dr Rodriguez-Otero on Data for Linvoseltamab in High-Risk Smoldering Myeloma

September 19th 2025

Paula Rodriguez-Otero, MD, discusses safety and efficacy findings with linvoseltamab, a bispecific antibody targeting BCMA, in patients with high-risk smoldering multiple myeloma.

Belantamab Mafodotin Triplet Yields Responses With Low Ocular Toxicity in Intermediate-Fit or Frail Newly Diagnosed Myeloma

September 19th 2025

Belantamab mafodotin plus lenalidomide and dexamethasone induced CRs or better in over half of patients with newly diagnosed multiple myeloma.

Co-Infusion of Anti-GPRC5D/Anti-BCMA Therapies Is Feasible, Yields Durable Responses in R/R Multiple Myeloma

September 19th 2025

Administering the anti-GPRC5D agent MCARH109 and anti-BCMA therapy MCARH125 in tandem was feasible and tolerable in relapsed/refractory multiple myeloma.

Eque-Cel Demonstrates Activity in R/R Multiple Myeloma

September 19th 2025

Eque-cel was effective for the treatment of patients with relapsed/refractory multiple myeloma.